JETREA Drug Profile
✉ Email this page to a colleague
Summary for Tradename: JETREA
| High Confidence Patents: | 3 |
| Applicants: | 1 |
| BLAs: | 1 |
| Recent Clinical Trials: | See clinical trials for JETREA |
Recent Clinical Trials for JETREA
Identify potential brand extensions & biosimilar entrants
| Sponsor | Phase |
|---|---|
| KU Leuven | Phase 1 |
| Katholieke Universiteit Leuven | Phase 1 |
| Universitaire Ziekenhuizen Leuven | Phase 1 |
Note on Biologic Patents
Matching patents to biologic drugs is far more complicated than for small-molecule drugs.
DrugPatentWatch employs three methods to identify biologic patents:
- Brand-side disclosures in response to biosimilar applications
- General brand-side disclosures
- Patents from broad patent text search
These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.
These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
1) High Certainty: US Patents for JETREA Derived from Brand-Side Litigation
No patents found based on brand-side litigation
2) High Certainty: US Patents for JETREA Derived from Company Disclosures
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Patent No. | Estimated Patent Expiration | Source |
|---|---|---|---|---|---|---|---|
| Thrombogenics Inc. | JETREA | ocriplasmin | Injection | 125422 | 7,445,775 | 2020-12-21 | Company disclosures |
| Thrombogenics Inc. | JETREA | ocriplasmin | Injection | 125422 | 7,547,435 | 2022-12-06 | Company disclosures |
| Thrombogenics Inc. | JETREA | ocriplasmin | Injection | 125422 | 7,914,783 | 2022-12-06 | Company disclosures |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Patent No. | >Estimated Patent Expiration | >Source |
3) Low Certainty: US Patents for JETREA Derived from Patent Text Search
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Patent No. | Estimated Patent Expiration | Source |
|---|---|---|---|---|---|---|---|
| Thrombogenics Inc. | JETREA | ocriplasmin | Injection | 125422 | 10,821,075 | 2037-07-12 | Patent claims search |
| Thrombogenics Inc. | JETREA | ocriplasmin | Injection | 125422 | 11,110,176 | Patent claims search | |
| Thrombogenics Inc. | JETREA | ocriplasmin | Injection | 125422 | 9,421,129 | 2032-04-02 | Patent claims search |
| Thrombogenics Inc. | JETREA | ocriplasmin | Injection | 125422 | 9,474,688 | 2031-10-25 | Patent claims search |
| Thrombogenics Inc. | JETREA | ocriplasmin | Injection | 125422 | 9,504,603 | 2032-04-02 | Patent claims search |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Patent No. | >Estimated Patent Expiration | >Source |
International Patents for JETREA
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Spain | 2296705 | ⤷ Subscribe |
| European Patent Office | 1343903 | ⤷ Subscribe |
| Japan | 2015131842 | ⤷ Subscribe |
| Denmark | 1343903 | ⤷ Subscribe |
| United Kingdom | 0031196 | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for JETREA
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 1390041-0 | Sweden | ⤷ Subscribe | MARKNADSGODKAENNANDE NR.: EU/1/13/819/001, 2013-03-15, MIKROPLASMIN |
| 13C0052 | France | ⤷ Subscribe | PRODUCT NAME: MICROPLASMINE; REGISTRATION NO/DATE: EU/1/13/819/001 20130315 |
| C20130023 00082 | Estonia | ⤷ Subscribe | PRODUCT NAME: OKRIPLASMIIN;REG NO/DATE: K(2013)1648 (LOPLIK) 13.03.2013 |
| CA 2013 00047 | Denmark | ⤷ Subscribe | PRODUCT NAME: MIKROPLASMIN HERUNDER OCRIPLASMIN; REG. NO/DATE: EU/1/13/819/001 20130313 |
| 163 8-2013 | Slovakia | ⤷ Subscribe | PRODUCT NAME: OKRIPLAZMIN; REGISTRATION NO/DATE: EU/1/13/819/001 20130313 |
| >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
